| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/716841/2013 (22.11.13) |
| Publication Date | 22/11/2013 |
| Content Type | News |
|
Iclusig is an anticancer medicine that contains the active substance ponatinib. It is used to treat adults with the certain types of leukaemia (cancer of the white blood cells). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in November 2013, made a number of recommendations to help minimise the risk of blood clots obstructing arteries or veins in patients taking Iclusig. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001968.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
